|Chemical and physical data|
|Molar mass||144.8 kg/mol|
Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.
This drug was developed by MedImmune, LLC.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|